Rectal Neoplasms Clinical Trial
Official title:
Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With Simultaneous Integrated Boost Intensity-modulated Radiotherapy in the Treatment of Locally Advanced Rectal Cancer
Verified date | October 2023 |
Source | First Affiliated Hospital of Guangxi Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study aims to evaluate the efficacy and safety of tislelizumab combined with simultaneous integrated boost intensity-modulated radiotherapy in treating locally advanced rectal cancer. To explore a new PD-1 inhibitor adjuvant chemotherapy model combined with radiotherapy to treat locally advanced rectal cancer.
Status | Recruiting |
Enrollment | 48 |
Est. completion date | August 31, 2026 |
Est. primary completion date | August 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. Aged 18 to 70 years. 2. The pathological type of rectal cancer diagnosed by histopathology is adenocarcinoma. 3. Patients with T3-4 in the eighth AJCC stage or positive regional lymph node and no distant metastasis. 4. Having at least one measurable lesion according to RECIST 1.1. 5. ECOG score 0-1. 6. Expected survival time =6 months. 7. Major organ function is normal, that is, meeting the following criteria: blood routine: HB=90g/L, ANC=1.5×109/L, PLT=80×109/L; Biochemical examination of ALB=30g/L, TBIL=1.5 ULN, ALT and AST=2.5 ULN, plasma Cr=1.5 ULN or creatinine clearance =60 ml/min. 8. Subjects volunteered to join the study, signed the informed consent, had good compliance, and cooperated with follow-up. Exclusion Criteria: 1. Patients have had or currently have other malignant tumors within 5 years. 2. Patients allergic or sensitive to any drug in the study protocol. 3. Patients innate or acquired immune deficiency (e.g. HIV infection). 4. The presence of any active, known or suspected autoimmune disease (such as, but not limited to, interstitial pneumonia, uveitis, enteritis, hepatitis, arthritis, nephritis, hypophysitis, hyperthyroidism, hypothyroidism, etc.); The subject had vitiligo. Subjects with asthma require bronchodilators for medical intervention. 5. The presence of active infections requiring systemic treatment. 6. The subject has previously received other PD-1 or PD-L1, or CTLA-4 antibody therapy, or other drug therapy targeting immunoregulatory receptor preparations. 7. Unrelieved toxic effects above CTCAE grade 1 due to any previous treatment, excluding alopecia. 8. Patients with a history of myocardial infarction or stroke, unstable angina pectoris, decompensated heart failure or deep vein thrombosis. 9. Patients with long-term untreated wounds or fractures, major surgical operations or severe traumatic injuries, fractures or ulcers within 4 weeks. 10. Pregnant or lactating women. 11. Patients with liver and kidney dysfunction. 12. Patients with a history of abuse of psychotropic drugs and unable to abstain or patients with mental disorders. 13. Patients who have participated in clinical trials of other drugs within 4 weeks. 14. Patients with concomitant diseases that, in the judgment of the investigator, seriously endanger the patient's safety or affect the patient's completion of the study. 15. The investigator judged that participation in this study was not conducive to the maximum benefit of the subjects. |
Country | Name | City | State |
---|---|---|---|
China | First Affiliated Hospital of Guangxi Medical University | Nanning | Guangxi |
Lead Sponsor | Collaborator |
---|---|
Yong Zhang,MD |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Complete response rate | Include in pathological complete response rate and clinical complete response rate. MRI/CT will be used for evaluating the carcinoma status. Pathological complete response rate will be evaluated by surgery. | 12 weeks~18 weeks | |
Secondary | Side effects | Myelosuppression, radiation enteritis, radiothermitis | 6monthes, 3years | |
Secondary | Overall survival | OS was calculated from the date of entry into the study to the date of death or the last follow-up visit. | 3 years | |
Secondary | Disease free survival | DFS was calculated from the date of entry into the study to the date of the time from the beginning of randomization to the disease recurrence or progression or death from any cause. | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02537340 -
PET/MR for Staging Rectal Cancer Patients With and Without EMVI-MR
|
||
Recruiting |
NCT02565667 -
A Prospective Clinical Study for Transanal Double Purse-string Rectal Anastomosis Preformed With KOL Stapler
|
N/A | |
Terminated |
NCT02538913 -
Exercise Training for Rectal Cancer Patients
|
N/A | |
Not yet recruiting |
NCT02439086 -
Prediction of Response to Neoadjuvant Therapy in Rectal Cancer
|
N/A | |
Completed |
NCT02233374 -
Predicting RadIotherapy ReSponse of Rectal Cancer With MRI and PET
|
N/A | |
Completed |
NCT00535652 -
Concentration of Ertapenem in Colorectal Tissue
|
Phase 4 | |
Completed |
NCT00535041 -
Pilot Trial of Pre-operative Chemo/RT Using Xeloda and External Beam RT Followed by Definite Surgery in Patients With Localized Rectal CA
|
N/A | |
Recruiting |
NCT04949646 -
Intraoperative Neuromonitoring of Pelvic Autonomous Nerve Plexus During Total Mesorectal Excision
|
N/A | |
Recruiting |
NCT04095468 -
Organ-preserving Management in Patients With Complete or Near-complete Tumour Response After Preoperative Radio(Chemo)Therapy for Rectal Cancer
|
||
Recruiting |
NCT05689775 -
Reconstruction After Abdominoperineal Resection With Robot-assisted Harvest of VRAM Flap
|
||
Recruiting |
NCT04006951 -
Development of a Clinical and Biological Database in Rectum Cancer
|
N/A | |
Recruiting |
NCT05068180 -
Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
|
Phase 4 | |
Recruiting |
NCT03714490 -
MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer
|
Phase 2 | |
Recruiting |
NCT03325361 -
The Role of Transanal Tube Drainage as A Mean of Prevention of Anastomotic Leakage Anastomotic Leakage
|
N/A | |
Completed |
NCT02252250 -
Transanal Total Mesorectal Excision Versus Laparoscopic TME for Rectal Cancer
|
N/A | |
Completed |
NCT01816607 -
Functional MRI of Hypoxia-mediated Rectal Cancer Aggressiveness
|
||
Completed |
NCT04455737 -
Ex Vivo Intra-arterial Indigo Carmine Injection After Transanal Total Mesorectal Excision
|
||
Completed |
NCT01721785 -
Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer
|
N/A | |
Active, not recruiting |
NCT01171300 -
Assessment of Response Before, During and After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients
|
N/A | |
Completed |
NCT01056913 -
NITI CAR27 (ColonRing) Compression Anastomosis in Colorectal Surgery
|
Phase 4 |